Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Nov;203(4):564-570.
doi: 10.1111/bjh.19117. Epub 2023 Oct 3.

The CD4/CD8 ratio of infused CD19-CAR-T is a prognostic factor for efficacy and toxicity

Eugenio Galli  1 , Silvia Bellesi  1 , Ilaria Pansini  2 , Giacomo Di Cesare  1 , Camilla Iacovelli  1 , Rosalia Malafronte  1   2 , Elena Maiolo  1 , Patrizia Chiusolo  1   2 , Simona Sica  1   2 , Federica Sorà  1   2 , Stefan Hohaus  1   2
Affiliations

The CD4/CD8 ratio of infused CD19-CAR-T is a prognostic factor for efficacy and toxicity

Eugenio Galli et al. Br J Haematol. 2023 Nov.

Abstract

CD4+ and CD8+ chimeric antigen receptor T cells (CAR-T) play different roles in the in vivo anti-tumour response, but the role of the CD4+ /CD8+ ratio among infused CAR-T has not been clearly defined yet. We analysed leftovers from infused anti-CD19 CAR-T bags of 31 patients with aggressive B-cell lymphomas. The median ratio was 1.44, lower for brexu-cel compared to tisa-cel and axi-cel. The CAR+CD4+ /CD8+ ratio was influenced by lactate dehydrogenase levels at apheresis, not by age, previous treatments or the CD4+ /CD8+ ratio in peripheral blood. Patients with a response at 3 months after CAR-T (M3) had a lower CAR+CD4+ /CD8+ ratio in the infused products compared to non-responders (ratio 0.74 vs. 2.47, p = 0.011). A CAR+CD4+ /CD8+ ratio higher than the cut point of 1.12 was associated with an increased risk of treatment failure at M3 (OR 23.3, p = 0.012) and M6 (OR 10, p = 0.028). The median 6-month PFS was 76% for patients with a ratio lower than 1.12% vs. 31% for the others. The prognostic role of the CAR+CD4+ /CD8+ ratio was independent of the costimulatory domain (CD28 vs. 4-1BB) of the product (OR 16.41, p = 0.041). Our data indicate a crucial role for CD8+ CAR-T and the CAR+CD4+ /CD8+ ratio in predicting CAR-T efficacy.

Keywords: CAR-T cells; CD4/CD8 ratio; apheresis; phenotype; prognostic factors.

PubMed Disclaimer

References

REFERENCES

    1. Larson RC, Maus MV. Recent advances and discoveries in the mechanisms and functions of CAR T cells. Nat Rev Cancer. 2021;21:145-161.
    1. Selli ME, Landmann JH, Terekhova M, Lattin J, Heard A, Hsu Y-S, et al. Costimulatory domains direct distinct fates of CAR-driven T-cell dysfunction. Blood. 2023;141:3153-3165. https://doi.org/10.1182/blood.2023020100
    1. Westin JR, Kersten MJ, Salles G, Abramson JS, Schuster SJ, Locke FL, et al. Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed/refractory aggressive B-cell lymphomas: observations from the JULIET, ZUMA-1, and TRANSCEND trials. Am J Hematol. 2021;96:1295-1312.
    1. Cuffel A, Allain V, Faivre L, Di Blasi R, Morin F, Vercellino L, et al. Real-world characteristics of T-cell apheresis and clinical response to tisagenlecleucel in B-cell lymphoma. Blood Adv. 2022;6:4657-4660.
    1. Rejeski K, Jain MD, Smith EL. Mechanisms of resistance and treatment of relapse after CAR T-cell therapy for large B-cell lymphoma and multiple myeloma. Transplant Cell Ther. 2023;29:418-428. https://doi.org/10.1016/j.jtct.2023.04.007

Publication types

LinkOut - more resources